Ameriprise
ANRO icon

Ameriprise’s Alto Neuroscience ANRO Stock Holding History

Ameriprise’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$300K Sell
13,324
-163
-1% -$3.02K ﹤0.01% 3763
2025
Q4 		$240K Hold
13,487
– – ﹤0.01% 3873
2025
Q3 		$54.2K Sell
13,487
-95
-0.7% -$315 ﹤0.01% 4016
2025
Q2 		$29.9K Sell
13,582
-1,687
-11% -$4.01K ﹤0.01% 3934
2025
Q1 		$33K Sell
15,269
-6,746
-31% -$24.1K ﹤0.01% 3960
2024
Q4 		$93.1K Buy
22,015
+1,359
+7% +$8.48K ﹤0.01% 3960
2024
Q3 		$236K Buy
+20,656
New +$253K ﹤0.01% 3710

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise's ANRO Position: Q1 2026 in Review

Ameriprise reduced its Alto Neuroscience (ANRO) stake by 1.2% in Q1 2026, selling an estimated $3.02K and leaving 13,324 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #3763.

Ameriprise first reported a position in ANRO in Q3 2024 and has held it in 7 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Ameriprise held 13,324 shares of Alto Neuroscience worth $300K as of Q1 2026.
  • Ameriprise sold 163 Alto Neuroscience shares in Q1 2026, an estimated $3.02K.
  • Alto Neuroscience made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3763 holding.
  • Ameriprise first reported a position in Alto Neuroscience in Q3 2024 and has held it in 7 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.